Table 4 Functional and oncologic outcomes
Follow-up, months, mean (range) | 37.3 (3 to 52) |
Continence, % | |
Daytime | 88 |
Nighttime | 55.1 |
Erectile dysfunction (%) | 46 |
Recurrences (%) | 1 (1.6) |
Distant metastasis (%) | 13 (21) |
Cancer-specific survival (%) | 84 |
Overall survival (%) | 71 |